CV Sciences Q2 Revenue Drops 17.5%, Going Concern Warning Reiterated
CVSI sits 69% above its 52-week low of $0.015.
Summary
CV Sciences' Q2 revenue fell 17.5% to $2.985M, net loss widened to $775K, and the going concern warning was reiterated with only $266K cash. Convertible note conversions issued 28.9M shares in H1 at $0.04, with more conversions after quarter-end at $0.03, heavily diluting shareholders.
Key Events · Earnings and Guidance · CVSI
-
Revenue Declines 17.5%
Q2 2026 product sales fell to $2.985M from $3.620M a year ago, driven by lower sales volume from restrictive state regulations and out-of-stock issues. Six-month revenue declined 14.5% to $6.18M.
-
Net Loss Widens
Q2 net loss was $775K vs $261K last year, and six-month net loss was $1.418M vs $370K. The increase was driven by $471K in non-cash fair-value losses on convertible notes and $249K in debt conversion losses.
-
Going Concern Warning Reiterated
Cash was only $266K at June 30, 2026, with a working capital deficit of $64K. Management stated substantial doubt about the company's ability to continue as a going concern and dependence on additional capital.
-
Massive Dilution from Note Conversions
Investor converted $1.258M of Amended Notes into 28.9M shares in H1 2026 at $0.04 average. After quarter-end, another 12.7M shares were issued at $0.03, fully repaying one Amended Note. The stock trades at $0.02535, below the conversion price.
Analysis · CVSI · Life Sciences
CV Sciences reported a 17.5% year-over-year revenue decline to $2.985 million in Q2 2026, with a net loss of $775K. The company reiterated its going concern warning, holding only $266K in cash and a $64K working capital deficit. Convertible note conversions are heavily diluting shareholders — 28.9 million shares were issued in the first half at an average of $0.04, and another 12.7 million shares were converted after quarter-end at $0.03. The stock trades at $0.02535, below the conversion price, meaning the investor can sell shares at a loss and trigger true-up notes, creating a potential dilution spiral. Regulatory uncertainty adds further pressure: the 2026 Act restricting hemp-derived products takes effect November 12, 2026, with a Senate-approved 29-day delay still pending House approval.
At the time of this filing, CVSI was trading at $0.03 on OTC in the Life Sciences sector, with a market capitalization of approximately $5.2M. The 52-week trading range was $0.02 to $0.10. This filing was assessed with negative market sentiment and an importance score of 8 out of 10.